Press Release Services and Business News from Send2Press, a unit of Neotrope, established 1983
Press Release Writing and Distribution
  Sunday, December 04, 2016 Neotrope®
Public Relations
Press Release Services and Media Relations
Send2Press® - Press Release Writing, Newswire Distribution, Press Release Optimization, Internet Marketing, Podcasting, SEO, Media Monitoring, Media Coaching, News Syndication, Book Marketing, Entertainment News, Web PR, and Media Relations since 1983   media relations
press release writing
Press Release Services and Business News from Send2Press, a unit of Neotrope, established 1983
 
NEWS WIRES:
» Ad Industry News
» Aerospace News
» Arts News
» Automobile News
» Biotech News
» Book News
» Business News
» Computer Industry News
» Construction News
» DotCom News
» eCommerce News
» Education News
» eMarketing News
» Entertainment News
» Employment News
» Energy News
» Family/Parenting News
» Fashion Industry News
» Fitness Industry News
» Food & Cooking News
» Graphics News
» Insurance News
» Interior Design News
» Internet News
» Investor News
» Manufacturing News
» Medical News
» Music News
» NonProfit News
» Peace/Ecology News
» Podcasting News
» Political News
» Real Estate News
» Religion News
» Retail News
» Security Solutions News
» Small Cap & OTC News
» Software Industry News
» Sports News
» Telecom News
» Travel Industry News
» TV & Cable News
» VoIP News
» US Newswires
» Business Profiles
» More News Channels
» Today's Headlines

Distribute your News with Send2Press® Press Release Services

 

Biotech News
PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE

NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.

Article Editor: Carly Zander


First American Gains Therapeutic Benefit From REXIN-G, The Leading Tumor-Targeted Gene Therapy Vector For Pancreatic Cancer

LOS ANGELES, Calif. - May 13, 2004 /Send2Press Newswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com), today announced that the first American with advanced pancreatic cancer has responded favorably to Rexin-G, the leading tumor- targeted injectable gene therapy vector for metastatic cancer. While Epeius Biotechnologies Corporation has recently gained FDA approval to open Phase I/II clinical trials in the United States, the first American patient opted to travel to Manila, Philippines, to receive the gene therapy intervention there, where the first clinical studies using Rexin-G for pancreatic cancer were conducted (International Journal of Oncology, January, 2004).

Over a one-month period, Rexin-G induced a progressive reduction in the size of his pancreatic tumor, and disappearance or shrinkage of his liver tumors without serious side effects.

The landmark clinical trial in cancer gene therapy was conducted by Drs. Conrado Lorenzo III and Gerardo H. Cornelio in a world-class tertiary care hospital in Manila. The clinical trials using Rexin-G for pancreatic cancer and other solid tumors in Manila is the result of a global initiative of Drs. Frederick L. Hall and Erlinda M. Gordon, founders of Epeius Biotechnologies Corporation to bring this targeted cancer intervention to the world. Dr. Gordon, an Asian-American physician/ scientist was recently awarded a plaque of recognition and a proclamation for her contributions in the field of biotechnology by the City of Los Angeles Mayor (James K. Hahn) and Councilmen.

Rexin-G gained U.S. FDA orphan drug approval for pancreatic cancer in the Fall of 2003, providing further product validation and exclusivity in the marketplace for years to come.

In a statement to the press, Dr. Hall, President and CEO of Epeius Biotechnologies remarked that, "The realization that Rexin-G works well in Americans too could catalyze the financial support needed to rapidly expand the clinical trials in the United States."

However, when questions about curing cancer inevitably arose, Dr. Hall emphasized caution: "We know that the implications of the TDS [targeted delivery system] technology are profound. However, while the targeting technology is indeed effective in delivering cancer-killing genes to metastatic tumors, and we are accumulating clinical evidence that Rexin-G is effective in pancreatic cancer, discussions about a 'cure' is premature, as this conclusion can only be made after extensive critical analysis of the results of a large number of clinical trials has been performed."

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company whose mission is to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genes and molecular therapeutics preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage.

Its lead product, Rexin-G, is the first tumor-targeted injectable gene therapy vector that has been approved by both the U.S. FDA and the Philippine BFAD (FDA counterpart) for use in Phase I/II clinical trials for pancreatic and colon cancer.



• Previous News from Epeius Biotechnologies Corporation





DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.

USE OF THE ABOVE NEWS ARTICLE
Article is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article.



Add Our News Headlines to Your Website Free
Free headline feed


Journalists & Editors
Choose your news by preferred topic(s).
Privacy protected.
MORE INFO

Archived Releases

Most Recent Releases


Subscribe to RSS Feed



NOTICE: THIS PAGE IS ARCHIVAL CONTENT AND SHOULD NOT BE RELIED UPON FOR ACCURACY.
Top of Page | Home Page | E-mail This Article to Someone

Press Release Services from Send2Press
Learn More About Press Release Services & Business Promotion by Neotrope®
Affordable Online Newswire Services   |   Press Release Writing and Editing
business news
 Copr. © 1983-2014 Neotrope® — all rights reserved. Privacy/Legal Statements 
Press Release Writing
Business Press Release Services | Compare News Distribution Plans | Agency Program | How to Order
PR Services Add-on Options | Price List | SEO+PR™ Services | Press Release Writing | Publication Lists
Client Testimonials | About Us | Contact Us | Newswire Channels |
News About Send2Press | | RSS/XML Feed

Free News Articles